Greenwich LifeSciences (NASDAQ:GLSI) Posts Earnings Results, Misses Estimates By $0.06 EPS

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) announced its earnings results on Monday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06), FiscalAI reports.

Greenwich LifeSciences Stock Down 7.9%

Shares of GLSI stock traded down $1.18 during trading hours on Monday, hitting $13.76. 153,544 shares of the company’s stock traded hands, compared to its average volume of 204,451. The stock’s fifty day simple moving average is $16.57 and its two-hundred day simple moving average is $21.06. Greenwich LifeSciences has a 12-month low of $7.78 and a 12-month high of $34.10. The stock has a market cap of $201.97 million, a price-to-earnings ratio of -8.94 and a beta of 1.57.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GLSI. Weiss Ratings downgraded shares of Greenwich LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. HC Wainwright raised their price objective on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Greenwich LifeSciences presently has an average rating of “Hold” and a consensus price target of $69.00.

Check Out Our Latest Report on GLSI

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

Read More

Earnings History for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.